Dr. Guisheng Song is a highly esteemed and globally recognized expert renowned for his pioneering research on the intricate role of microRNAs in regulating the pathogenesis of Metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatocellular carcinoma (HCC). With a distinguished academic background, he earned his PhD from the prestigious Chinese Academy of Sciences, followed by comprehensive post-doctoral training in Gastroenterology, Hepatology, and Molecular Biology at distinguished institutions like the Mayo Clinic and the University of California, San Francisco, specializing in liver diseases and signal transduction. In 2012, Dr. Song joined the esteemed Department of Medicine at the University of Minnesota as a tenure-track faculty member, where he has made remarkable contributions to the field. Recognizing his exceptional expertise and accomplishments, he was granted tenure in 2019 and promoted to the rank of Full Professor in 2023.
Over the past 13 years, Dr. Song's illustrious laboratory has been at the forefront of pioneering research, focusing on unraveling the intricate mechanisms by which microRNAs modulate the pathogenesis of MAFLD and HCC. His groundbreaking work has consistently secured substantial funding from esteemed institutions such as the National Institutes of Health (NIH), American Cancer Society and various industry sponsors since 2012. Dr. Song's exceptional research findings have been published in numerous top-tier peer-reviewed journals, including but not limited to Hepatology, Gastroenterology, Journal of Hepatology, Gut, Journal of Clinical Investigation, Metabolism, and Oncogene. Recognized for his unparalleled expertise and contributions to the field, Dr. Song serves as a distinguished board member for Hepatology and holds influential advisory roles for numerous other esteemed journals. In light of his exceptional scientific contributions, he has received numerous prestigious awards, including the highly coveted American Cancer Society Research Award, NIH CTSI KL2 Scholar Award, and Gilead Research Scholar Award. Furthermore, Dr. Song actively contributes to various committees within esteemed organizations such as the American Cancer Society and the American Association for the Study of Liver Diseases (AASLD).
Dr. Guisheng Song's research is marked by an unwavering commitment to conceptual innovation, exemplified by his groundbreaking work in developing microRNAs as a unique and revolutionary form of immunotherapy for the treatment of liver cancer. Recognizing the limitations of current immunotherapies, Dr. Song has spearheaded the development of microRNA-based approaches that hold great promise in addressing the low response rates observed in liver cancer treatment. In fact, his visionary research has led to the initiation of preclinical trials for two microRNA-based immunotherapies, showcasing his pioneering efforts in translating scientific discoveries into potential clinical applications. Dr. Song's remarkable contributions not only advance our understanding of the intricate mechanisms underlying MAFLD and HCC, but they also lay the foundation for transformative microRNA-based immunotherapies targeting both conditions. By utilizing microRNAs as powerful tools for modulation, he has opened new avenues for developing innovative therapeutic strategies with the potential to revolutionize the treatment landscape. As a globally recognized and highly influential leader in the field of microRNA and liver diseases, Dr. Song brings invaluable expertise and transformative insights to the hepatology community, solidifying his status as an indispensable and revered member of the organization.